Get the Stockscreener App
0.65
6.00%
-0.0415
After Hours:
.65
Novabay Pharmaceuticals Inc stock is traded at $0.65, with a volume of 231.57K.
It is down -6.00% in the last 24 hours and up +10.73% over the past month.
NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets non-antibiotic and anti-infective products for the eye care market in the United States, China, and internationally. It offers Avenova, a prescription product for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye; NeutroPhase for wound care market; CelleRx for the aesthetic dermatology market; Aganocide compounds patented synthetic molecules for use against bacteria, viruses, and fungi; auriclosene irrigation solution for urology; and intelli-Case, a device for soft and rigid gas permeable contact lenses. NovaBay Pharmaceuticals, Inc. has collaboration and license agreement with Virbac to develop auriclosene, a proprietary compound for veterinary markets. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is based in Emeryville, California.
See More
Previous Close:
$0.6915
Open:
$0.708
24h Volume:
231.57K
Relative Volume:
0.42
Market Cap:
$3.18M
Revenue:
$14.64M
Net Income/Loss:
$-13.74M
P/E Ratio:
-0.0894
EPS:
-7.27
Net Cash Flow:
$-5.04M
1W Performance:
-8.46%
1M Performance:
+10.73%
6M Performance:
+0.31%
1Y Performance:
-88.61%
1-Day Range:
$0.60
$0.7113
1-Week Range:
$0.60
$0.72
52-Week Range:
$0.3611
$9.079
Novabay Pharmaceuticals Inc Stock (NBY) Company Profile
Name
Novabay Pharmaceuticals Inc
Sector
Industry
Phone
510-899-8800
Address
2000 Powell Street, Suite 1150, Emeryville, CA
Compare NBY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NBY
Novabay Pharmaceuticals Inc
|
0.65 | 3.18M | 14.64M | -13.74M | -5.04M | -7.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.67B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 74.97B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.50B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 29.63B | 3.30B | -501.07M | 1.03B | -2.1146 |
Novabay Pharmaceuticals Inc Stock (NBY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-18-19 | Initiated | Ladenburg Thalmann | Buy |
| Jul-06-18 | Reiterated | H.C. Wainwright | Buy |
| Nov-15-17 | Reiterated | Laidlaw | Buy |
| Jun-05-17 | Initiated | ROTH Capital | Buy |
| Mar-27-17 | Initiated | Laidlaw | Buy |
| Feb-06-17 | Initiated | Rodman & Renshaw | Buy |
| Mar-07-16 | Downgrade | Maxim Group | Buy → Hold |
| Dec-14-15 | Reiterated | Maxim Group | Buy |
| Apr-30-15 | Resumed | Maxim Group | Buy |
| Mar-06-13 | Initiated | Ascendiant Capital Markets | Strong Buy |
| Jan-03-08 | Initiated | Dawson James | Speculative Buy |
View All
Novabay Pharmaceuticals Inc Stock (NBY) Latest News
NovaBay Pharmaceuticals (NYSE:NBY) Coverage Initiated at StockNews.com - Defense World
**NovaBay Pharmaceuticals Completes Asset Sale Transaction and Plans for Dissolution**** - Defense World
NovaBay Pharma’s Strategic Shift and Liquidation Plans - TipRanks
NovaBay Completes $11.5M Avenova Sale to PRN, Pursues Full Company Dissolution - StockTitan
NovaBay Pharmaceuticals Extends CEO’s Employment Agreement Until 2025 - Defense World
NovaBay extends CEO's contract through 2025 By Investing.com - Investing.com South Africa
NovaBay extends CEO's contract through 2025 - Investing.com India
NovaBay Pharmaceuticals (NYSE:NBY) Coverage Initiated by Analysts at StockNews.com - Defense World
NovaBay Pharmaceuticals Completes Sale of Wound Care Product Trademarks and Inventory - Defense World
NovaBay Pharmaceuticals (NYSE:NBY) Now Covered by Analysts at StockNews.com - Defense World
Novabay Pharmaceuticals Announces Board Changes - Marketscreener.com
NovaBay Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Shares Cross Above 50 Day Moving Average – Should You Sell? - Defense World
NovaBay Pharmaceuticals (NYSE:NBY) Now Covered by StockNews.com - Defense World
NovaBay Pharmaceuticals (NBY) Upgraded to Buy: Here's Why - Yahoo Finance
NovaBay Pharmaceuticals Adjourns Special Meeting Due to Insufficient Votes - Defense World
NovaBay Pharmaceuticals Announces the Further Adjournment of the Special Meeting of Stockholders - BioSpace
NovaBay Pharmaceuticals Delays Critical Vote on Avenova Sale and Company Dissolution Amid Vote Shortage - StockTitan
NovaBay®Pharmaceuticals, Inc. Launches NovaWipes Eyelid Wipes on Amazon.com - Marketscreener.com
NovaBay Pharmaceuticals (NYSE:NBY) Earns Hold Rating from Analysts at StockNews.com - Defense World
NBYNovaBay Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
NovaBay CEO Letter to Stockholders Urges a FOR Vote at Upcoming Reconvened Special Meeting - BioSpace
NovaBay Pharmaceuticals Urges Critical Vote on Eyecare Business Sale to PRN, Company Dissolution - StockTitan
NovaBay Pharmaceuticals to Reconvene Special Meeting of Stockholders on December 18, 2024 - BioSpace
NovaBay Postpones Key Vote on Asset Sale, Liquidation Plans Amid Low Turnout | NBY Stock News - StockTitan
NovaBay calls for affirmative vote on asset sale and dissolution - Investing.com
NovaBay calls for affirmative vote on asset sale and dissolution By Investing.com - Investing.com UK
NovaBay Pharmaceuticals Reports Q3 2024 Financials Amid Strategic Changes - TipRanks
NovaBay Pharmaceuticals Reports Third Quarter 2024 Results, Accepts Revised Offer to Sell Avenova Brand - Vision Monday
NovaBay Pharmaceuticals Reports Third Quarter 2024 Financial Results - StockTitan
NovaBay accepts higher PRN offer, says Refresh deal no longer superior - MSN
NovaBay agrees to increased offer for eyecare unit - Investing.com
NovaBay agrees to increased offer for eyecare unit By Investing.com - Investing.com UK
NovaBay Pharmaceuticals Accepts Revised Offer from PRN Physician Recommended Nutriceuticals, LLC and Enters into an Amendment to the Asset Purchase Agreement to Increase Purchase Price - StockTitan
NovaBay Pharmaceuticals : Signs Distribution Agreement With the Biopharm Group - Marketscreener.com
# NovaBay Pharmaceuticals Considers Acquisition Offer in Recent SEC Filing - Defense World
NovaBay Pharmaceuticals receives unsolicited offer from Refresh Acquisitions - MSN
NovaBay Pharmaceuticals Board Determines Unsolicited Offer is Superior to Asset Purchase Agreement with PRN Physician Recommended Nutriceuticals, LLC - StockTitan
NovaBay to sell Avenova assets - Healio
NovaBay Pharmaceuticals Signs Definitive Agreement to Sell Its Avenova AssetsVision Monday - Vision Monday
Novabay Pharmaceuticals Inc (NBY) Stock: A Year of Market Fluctuations - The InvestChronicle
Before You Invest, Make Sure You Check This Novabay Pharmaceuticals Inc (AMEX: NBY) Analysis - Stocks Register
Novabay Pharmaceuticals Inc (NBY)’s Market Momentum: Closing Strong at 0.70, Down -5.62 - The Dwinnex
NovaBay Pharmaceuticals, Inc. announced that it expects to receive $2.83 million in funding from Pioneer Pharma Pte. Ltd. and other investors. - Marketscreener.com
A new trading data show Novabay Pharmaceuticals Inc (NBY) is showing positive returns. - SETE News
Kuehn Law Encourages COFS, ARC, RFL, and NBY Investors to Contact Law Firm - PR Newswire
What's Going On With NovaBay Pharmaceuticals Shares Friday? - Benzinga
NBY’s price-to-free cash flow ratio: What it means for investors - US Post News
NovaBay sells Avenova brand to PRN for $9.5 million - Investing.com
PRN Nutriceuticals agreed to acquire Assets of Avenova Brand and Business of NovaBay Pharmaceuticals, Inc.. - Marketscreener.com
Novabay Pharmaceuticals Inc Stock (NBY) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):